

REGISTERED COMPANY NUMBER: 02747551 (England and Wales)
REGISTERED CHARITY NUMBER: 1039411

Report of the Trustees and
Unaudited Financial Statements
for the Year Ended 31st January 2021
for
Safer Medicines Trust

Spencer Hyde Limited
272 Regents Park Road
London
N3 3HN

Safer Medicines Trust

Contents of the Financial Statements
for the Year Ended 31st January 2021

	Page
Reference and Administrative Details	1
Report of the Trustees	2 to 3
Independent Examiner's Report	4
Statement of Financial Activities	5
Statement of Financial Position	6
Notes to the Financial Statements	7 to 10

Safer Medicines Trust

Reference and Administrative Details
for the Year Ended 31st January 2021

TRUSTEES	K Archibald J Bailey B Gajek
COMPANY SECRETARY	R Macklin
REGISTERED OFFICE	272, Regents Park Road Finchley Central London N3 3HN
REGISTERED COMPANY NUMBER	02747551 (England and Wales)
REGISTERED CHARITY NUMBER	1039411
INDEPENDENT EXAMINER	Spencer Hyde Limited 272 Regents Park Road London N3 3HN

Safer Medicines Trust
Report of the Trustees
for the Year Ended 31st January 2021

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st January 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

Safer Medicines Trust is established to :-

- a) undertake and advance research into the effectiveness and benefit to the general public of medical experiments on animals;
- b) provide information and to educate the public as to the results of such research;
- c) do any other charitable activity.

ACHIEVEMENT AND PERFORMANCE

Charitable activities and achievements

In March, alongside several of our Alliance for Human Relevant Science partners, we launched our joint white paper: "Accelerating the Growth of Human Relevant Sciences in the United Kingdom" in Parliament. Several MPs attended and signed Early Day Motion (EDM) 256: "Accelerating human relevant life sciences in the UK", which was launched by Sir David Amess MP on the same day. 103 MPs signed this EDM, making it the 8th most popular out of 2,276 EDMs in the 2019-2021 parliamentary session, showing just how important the issue is to MPs and their constituents. We sent a Briefing Document summarising the White Paper and its recommendations to every MP.

We worked with our Alliance partners and Grahame Morris MP to establish a new All-Party Parliamentary Group for Human Relevant Science. Grahame, as Chair, hosted its virtual launch in October and its first meeting in November, with excellent talks from some eminent speakers. He also asked Parliamentary Questions and helped us engage with ministers. Please see www.HumanRelevantScience.org for more details.

We joined with nearly 100 other scientists and organisations in signing an Open Letter to the World Health Organisation, national governments, funding bodies and regulators calling for human relevant methods to be prioritised to help the discovery of effective vaccines and treatments for Covid-19. We also co-authored an Open Letter to 10 regulatory bodies, which cited the Alliance White Paper and was published in the Guardian on 14th July.

Our Pharmaceutical Director, Dr Gerry Kenna, spoke at the Physicians Committee for Responsible Medicine (PCRM) US Congressional hearing "Confronting Covid-19: A Briefing on Prioritizing Human-Based Research". A recording of the event and Dr Kenna's slides are on our website, as are the letters above.

Our Director, Dr Jan Turner helped as an expert reviewer to award the "Fast-track grant for research on non-animal approaches to investigate mechanisms, medicines, and vaccines for coronaviruses" from the Johns Hopkins Center for Alternatives to Animal Testing, USA.

Dr Turner gave virtual presentations at the Advances in Cell and Tissue Culture conference, the American Society for Cellular and Computational Toxicology Annual Meeting, and a Westminster Health Forum meeting on Developing Methods and Technologies to Ensure Safe and Effective Medicines.

We had three scientific publications during the year, links to all of which are available via our website:

- 1) A paper in BMJ Open Science by Dr Pandora Pound and Rebecca Ram, entitled: "Are researchers moving away from animal models as a result of poor clinical translation in the field of stroke? An analysis of opinion papers."
- 2) A chapter by Dr Pound: "Animal models and the search for drug treatments for traumatic brain injury" in the book: Neuroethics and nonhuman animals, Johnson L, Fenton A, Shriver A (Eds). 2020, Springer, Switzerland.
- 3) Dr Pandora Pound guest edited a special issue of the journal 'Animals' entitled "Are Animal Models Needed to Discover, Develop and Test Pharmaceutical Drugs for Humans in the 21st Century?"

Safer Medicines Trust

Report of the Trustees for the Year Ended 31st January 2021

FINANCIAL REVIEW

Reserves policy

The Trustees have resolved to establish reserves with a reputable UK bank for future funding activities of the charity, and the Trustees have powers of investment in such assets as they see fit.

Financial Review

During the year, the Charity raised £25,718 (2020: £10,185) as voluntary donations.

These funds were used to promote the campaigns and educations through attendance at several conferences and events and overhead expenses.

As shown in the Statement of Financial Activities, the Charity still holds £42,207 (2020: £130,366) which will be used as the programmes progress.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The Charity is controlled by its governing document, a Memorandum and Articles of Association, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

The company is limited by guarantee and therefore has no share capital. Each Trustee's guaranteed liability is limited to £1.

It is the view of the Trustees and stated in the Memorandum and Articles of Association that the surplus of funds is not available for distribution to the Trustees but it is for the sole purpose of achieving the main objects of the charitable company.

Recruitment and appointment of new trustees

The management of the charity is the responsibility of the Trustees who are elected and co-opted under the terms of the Articles of Association.

The number of Trustees shall not be less than three but shall not be subject to any maximum. At every Annual General Meeting (AGM), one-third of the Trustees who are subject to retirement by rotation or, if their number is not three or a multiple of three, the number nearest to one-third shall retire from office, but, if there is only one Trustee who is subject to retirement by rotation, he or she shall retire. Additional Trustees can be appointed by recommendation of the existing Trustees or by standing for election at the AGM.

Induction and training of new trustees

All new Trustees, once elected, are inducted by the Chair Trustee, Ms K Archibald. All new Trustees are handed the charity's organisational policies and documents. All Trustees are encouraged to attend regular training courses made available through the NCVO, LVSC and other local voluntary support bodies such as HAVS, as well as utilising online resources for Trustees and attend networking opportunities.

Statement on Public Benefit

The Trustees have referred to the guidance issued by the Charity Commission's general guidance on public benefit when reviewing the Trust's aims and objectives and in planning its future activities.

In particular, we have considered how planned activities will contribute to the aims and objectives set.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on 28th October 2021 and signed on its behalf by:

K Archibald - Trustee

Independent Examiner's Report to the Trustees of
Safer Medicines Trust

Independent examiner's report to the trustees of Safer Medicines Trust ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st January 2021.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Antony Youselli
Spencer Hyde Limited
272 Regents Park Road
London
N3 3HN

28th October 2021

Safer Medicines Trust

Statement of Financial Activities
for the Year Ended 31st January 2021

		2021 Unrestricted fund £	2020 Total funds £
INCOME AND ENDOWMENTS FROM	Notes		
Donations and legacies		25,718	10,185
Investment income	2	183	320
Other income	3	19,509	-
Total		45,410	10,505
 EXPENDITURE ON			
Raising funds		5,229	3,086
Charitable activities			
General Activity		114,742	165,298
Other		13,598	6,792
Total		133,569	175,176
 NET INCOME/(EXPENDITURE)		(88,159)	(164,671)
 RECONCILIATION OF FUNDS			
Total funds brought forward		130,366	295,037
 TOTAL FUNDS CARRIED FORWARD		42,207	130,366

The notes form part of these financial statements

Safer Medicines Trust

Statement of Financial Position
31st January 2021

	Notes	2021 Unrestricted fund £	2020 Total funds £
CURRENT ASSETS			
Debtors	7	-	4,179
Cash at bank and in hand		47,853	132,074
		<u>47,853</u>	<u>136,253</u>
CREDITORS			
Amounts falling due within one year	8	(5,646)	(5,887)
		<u>42,207</u>	<u>130,366</u>
NET CURRENT ASSETS			
		<u>42,207</u>	<u>130,366</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			
		<u>42,207</u>	<u>130,366</u>
NET ASSETS			
		<u>42,207</u>	<u>130,366</u>
FUNDS	9		
Unrestricted funds		42,207	130,366
TOTAL FUNDS		<u>42,207</u>	<u>130,366</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st January 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st January 2021 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 28th October 2021 and were signed on its behalf by:

K Archibald - Trustee

Safer Medicines Trust

Notes to the Financial Statements for the Year Ended 31st January 2021

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - 25% on cost

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Vat

The charity is not registered for VAT (Value Added Tax). In common with many other similar charities, the expenses are inflated by VAT, which cannot be recovered.

Safer Medicines Trust

Notes to the Financial Statements - continued
for the Year Ended 31st January 2021

2. INVESTMENT INCOME

	2021	2020
	£	£
Deposit account interest	183	320
	<u> </u>	<u> </u>

3. OTHER INCOME

Included in the accounts is £19,509, (2020: Nil) in relation to Government CJRS Grant received during the year.

4. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31st January 2021 nor for the year ended 31st January 2020.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31st January 2021 nor for the year ended 31st January 2020.

5. STAFF COSTS

Included in the accounts is £57,400 (2020: £66,625) paid to Dr Jan Turner for her role as Executive Director.

6. TANGIBLE FIXED ASSETS

	Computer equipment £
COST	
At 1st February 2020 and 31st January 2021	2,251
	<u> </u>
DEPRECIATION	
At 1st February 2020 and 31st January 2021	2,251
	<u> </u>
NET BOOK VALUE	
At 31st January 2021	-
	<u> </u>
At 31st January 2020	-
	<u> </u>

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021	2020
	£	£
Other debtors	-	4,179
	<u> </u>	<u> </u>

Safer Medicines Trust

Notes to the Financial Statements - continued
for the Year Ended 31st January 2021

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021	2020
	£	£
Social security and other taxes	1,946	1,947
Net wages	2,740	2,740
Accrued expenses	960	1,200
	<u>5,646</u>	<u>5,887</u>

9. MOVEMENT IN FUNDS

	At 1.2.20	Net movement in funds	At 31.1.21
	£	£	£
Unrestricted funds			
General fund	130,366	(88,159)	42,207
	<u>130,366</u>	<u>(88,159)</u>	<u>42,207</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
General fund	45,410	(133,569)	(88,159)
	<u>45,410</u>	<u>(133,569)</u>	<u>(88,159)</u>

Comparatives for movement in funds

	At 1.2.19	Net movement in funds	At 31.1.20
	£	£	£
Unrestricted funds			
General fund	295,037	(164,671)	130,366
	<u>295,037</u>	<u>(164,671)</u>	<u>130,366</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
General fund	10,505	(175,176)	(164,671)
	<u>10,505</u>	<u>(175,176)</u>	<u>(164,671)</u>

Safer Medicines Trust

Notes to the Financial Statements - continued
for the Year Ended 31st January 2021

9. **MOVEMENT IN FUNDS - continued**

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.2.19 £	Net movement in funds £	At 31.1.21 £
Unrestricted funds			
General fund	295,037	(252,830)	42,207
TOTAL FUNDS	<u>295,037</u>	<u>(252,830)</u>	<u>42,207</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	55,915	(308,745)	(252,830)
TOTAL FUNDS	<u>55,915</u>	<u>(308,745)</u>	<u>(252,830)</u>

10. **RELATED PARTY DISCLOSURES**

There were no related party transactions for the year ended 31st January 2021.